Pre-made Alemtuzumab benchmark antibody ( Whole mAb, anti-CD52 therapeutic antibody, Anti-HE5/CDW52/EDDM5 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-015
Pre-Made Alemtuzumab biosimilar, Whole mAb, Anti-CD52 Antibody: Anti-HE5/CDW52/EDDM5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Alemtuzumab biosimilar, Whole mAb, Anti-CD52 Antibody: Anti-HE5/CDW52/EDDM5 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||1bey:HL/1ce1:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge|
|Conditions Approved||Chronic lymphocytic leukaemia;Multiple sclerosis|
|Conditions Active||Lymphoma;T-cell prolymphocytic leukaemia|
|Conditions Discontinued||Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma|